Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response

Approximately 50% of metastatic melanoma patients harbor BRAF mutations. Several treatment options including the combination of BRAF and MEK inhibitors (BRAF/MEKi) and immunotherapy (mainly anti CTLA-4 and anti PD-1 antibodies), have been shown to improve survival in these patients. Although preclin...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez-Cao, Maria, Boada, Aram, Teixidó, Cristina, Fernandez-Figueras, María Teresa, Mayo, Clara, Tresserra, Francesc, Bustamante, Jean, Viteri, Santiago, Puertas, Enrique, Santarpia, Mariacarmela, Riso, Aldo, Barron, Feliciano, Karachaliou, Niki, Rosell, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302939/
https://www.ncbi.nlm.nih.gov/pubmed/27447748
http://dx.doi.org/10.18632/oncotarget.10651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302939/
https://www.ncbi.nlm.nih.gov/pubmed/27447748
http://dx.doi.org/10.18632/oncotarget.10651

Ejemplares similares